SCHEMBL4289733

SCHEMBL4289733

CC(C)CCOc1ccc(C(=O)c2ccc(OCC(C)C)cc2OCC(C)C)cc1OCC(=O)O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FOS P01100 2/20 0.48
JUN P05412 2/20 0.48
MAPK1 P28482 1/20 0.43
PPARD Q03181 4/20 0.40
FFAR1 O14842 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
LMNA P02545 1/20 0.39
CYSLTR2 Q9NS75 1/20 0.38
CYSLTR1 Q9Y271 1/20 0.38
POLB P06746 2/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.37
PPARG P37231 1/20 0.36
PPARA Q07869 1/20 0.36
NR1H4 Q96RI1 1/20 0.36
TP53 P04637 1/20 0.36
RECQL P46063 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HTT P42858 1/20 0.36
CASP6 P55212 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4284962 0.94 MAPK1 (0.50) FOSJUNMAPK1PPARDMEN1
SCHEMBL4279733 0.94 FOS (0.54) FOSJUNPPARDFFAR1MEN1
SCHEMBL4289725 0.88 HPGD (0.44) FOSJUNMAPK1KMT2ALMNA
SCHEMBL4279655 0.85 FOS (0.56) FOSJUNMAPK1PPARDPPARG
SCHEMBL4277481 0.81 HPGD (0.47) MAPK1KMT2ALMNAPOLBTP53
SCHEMBL4284432 0.81 HPGD (0.49) FOSJUNMEN1KMT2ALMNA
SCHEMBL4279133 0.80 FOS (0.49) FOSJUNMAPK1POLBNR1H4
SCHEMBL4279676 0.79 FOS (0.52) FOSJUNMAPK1MEN1KMT2A
SCHEMBL4289803 0.79 FOS (0.54) FOSJUNLMNANR1H4
SCHEMBL4279716 0.78 FOS (0.63) FOSJUNMAPK1POLBNR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090118169-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2009-05-07 US disclosed
US-7314888-B1 Compounds and medicinal use thereof TOYAMA CHEMICAL CO., LTD. (JP) 2008-01-01 US disclosed
EP-1127869-A1 NOVEL COMPOUNDS AND MEDICINAL USE THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2001-08-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118169-A1 NOVEL COMPOUNDS AND PHARMACEUTICAL USE THEREOF SP1, AP1G1, AP1M1 FOS 63/4885JUN 20/4885MAPK1 763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.